Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2000

View Archived Issues

Barr submits IND for Seasonale oral contraceptive

Phase I/II results for oral candidiasis treatment for HIV/AIDS patients

CytoTherapeutics changes name to StemCells

Immtech's DB-289 proves effective against African sleeping sickness

Maxim sells MaxVax mucosal vaccine technology

Progenics to continue GMK cancer vaccine trial as an extension study

BLS initiates inosine development program as stroke therapy

Guilford signs definitive merger agreement with Gliatech

TOBI trial in young CF patients with mild lung disease commences; European patent granted

Repligen acquires U.S. patent rights to CTLA4-Ig

Olux approved for U.S. marketing

PI-88 under development for cardiovascular indication; Progen enters strategic alliance

Xenova releases data from phase II colorectal cancer trial

Bayer decides to discontinue development of Bay-44-3428 for asthma

Development progresses for Nuvance in the treatment of asthma

Alizyme acquires renzapride, receives equity investment from SmithKline Beecham

In vitro and clinical data for daptomycin presented at ECCMID; Cubist accelerates development

Efforts to develop malaria vaccines reviewed at ECCMID; new candidate from SB highlighted

Merck carbapenem continues to yield positive results in preclinical and clinical studies

No efficacy seen for 9-AC in phase II trial in AIDS-related KS

Visudyne therapy receives Canadian approval for treatment of wet AMD

Use of pregabalin and related compounds for mania and bipolar disorder

BDNF reported to be useful for liver diseases

Antibodies to von Willebrand factor that act only at sites of thrombus formation

Joint research at Novo Nordisk and Dr. Reddy's covered by multiple patents

Natural protein with the ability to abrogate certain toxic effects of TNF

Novel class of inhibitors of cysteine proteases of the ICE/ced-3 family designed by Idun

Sagami discovers antitumor lipopeptides produced by fungus

Inhibitors of nitric oxide synthase synthesized at Schering AG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...